Newpath Partners

Newpath Partners is a life science and biotechnology venture firm dedicated to excellent science and to forming partnerships based on trust and a shared vision. The firm focuses on creating companies that pioneer transformative therapeutics to mitigate suffering and death from disease. Newpath Partners is committed to supporting scientific entrepreneurs at the earliest stages of company development, empowering them to translate their discoveries into treatments for patients living with a broad range of diseases without adequate therapies or cures. The firm's investment strategy emphasizes breakthrough innovations and scalable solutions, with a particular focus on biotechnology and life sciences sectors. Newpath Partners has a history of launching and supporting numerous companies, including Prime Medicine, Chroma Medicine, Kojin Therapeutics, Exo Therapeutics, Kisbee Therapeutics, and Myeloid Therapeutics. The firm is led by Thomas J. Cahill, M.D., Ph.D., who has been instrumental in aligning interests between academic scientists, investors, and management teams. Under his leadership, Newpath Partners has been actively involved in various companies, demonstrating a commitment to advancing novel therapeutics and fostering innovation in the life sciences industry. The firm's approach combines a deep understanding of science with a dedication to translating discoveries into solutions, aiming to change the status quo in medicine and address unmet medical needs. Newpath Partners continues to support scientists tackling the greatest needs in medicine, aligning with investors who share a vision for a new future of healthcare. The firm's ethos is guided by the principle of doing the right thing, fostering an environment where good things happen through trust and collaboration. This principle has attracted the continued support of investors and bold ideas from leading scientists, enabling Newpath Partners to build adept management teams and support the growth of innovative life sciences companies.